AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05565118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Surgical Treatment
Description: During this surgery, participants will also undergo a tissue biopsy at recording sites for correlation to neural recording data.
Study NCT05565118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Electrocorticography
Description: Each participant will undergo intraoperative electrocorticography (ECOG) through subdural grid (SDG) and depth electrode (DE) via FDA-cleared, standardized, brain recording technology.
Study NCT06166524 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation for atrial fibrillation using pulsed-field energy
Description: Patients will undergo pulmonary vein isolation using pulsed-field energy
Study NCT06166524 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conservative arm
Description: Patients will undergo electrical cardioversion with consequent treatment with antiarrhythmic drugs
Study NCT04825912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self System Therapy for Older Adults with Advanced Lung Cancer (SST-LC) Resilience
Description: The SST-LC is a brief structured intervention deliverable by video conference. The SST-LC Resilience protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors. The focus will be to test measures of resilience during the intervention period.
Study NCT05487417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline is a tetracycline antibiotic. Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.
Study NCT05407155 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: bevacizumab plus nab-paclitaxel and platinum
Description: Bevacizumab is given as 15mg/kg every 3 weeks. Nab-paclitaxel is given as 260 mg/m2 every 3 weeks for 4 cycles at most. Platinum includes caboplatin or cisplatin, which is chosed by phycisians. Carboplatin was calculated using AUC equals 5 for 4 cycles at most, and cisplatin was given as 75mg/m2 for 4 cycles at most. Bevacizumab is given untill disease progression or intolerated toxicities.
Study NCT04864028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: 15min sitting, 15min standing, 15min sitting, 15 min low intensity cycling
Study NCT05892094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance and Aerobic Training
Description: For aerobic exercise, participants will do brisk walking 30 minutes in the first two weeks, 3-6. weeks will be 35 minutes, 7th and 8th weeks will be 40 minutes.The first and last 10 minutes of each walk will be said to be done at a slow pace, for the warm-up and cool-down periods. Participants will be called regularly to monitor their participation in the aerobic exercise program, and their compliance with the exercise will be checked, and they will be motivated to continue the exercises by providing the necessary information. Resistance exercises sessions will include five minutes of warm-up, forty minutes of resistance training and five minutes of cool-down. The training load will be provided by progressively increasing the repetitions. The Borg Scale will be used to adjust the exercise intensity. Rest time between sets will be 60 seconds.
Study NCT06376058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroprocaine 1% Injectable Solution
Description: • in parturients allocated to the chloroprocaine group, a fixed dose of chloroprocaine 1% will be administered intrathecally
Study NCT06376058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75% Injectable Solution
Description: • in parturients allocated to the ropivacaine group, a fixed dose of ropivacaine 0.75% will be administered intrathecally
Study NCT04875351 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test
Description: The BCI test provides a quantitative estimate of the risk for both late (post-5 years from diagnosis) distant recurrence and of the cumulative distant recurrence risk over 10 years (0-10y) in patients treated with adjuvant endocrine therapy (LN- patients) or adjuvant chemoendocrine therapy (LN+ patients), and prediction of the likelihood of benefit from extended (>5 year) endocrine therapy.
Study NCT06583213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Spinal Anaesthesia.
Description: An intrathecal catheter 20 G will be then inserted 4-5 cm into the intrathecal space.This technique of SA will be performed on all patients , the needle should be inserted between L3 and L4 space or L4 and L5 space in order to avoid injury to the spinal cord. An intrathecal mixture (5mL) containing 3 mg/ml hyperbaric bupivacaine and 1 μg/ml dexmedetomidine will be prepared. Intrathecal anaesthesia will be induced by giving 2 mL (6 mg of hyperbaric bupivacaine and 2 μg of dexmedetomidine ) of the mixture, followed by a second 2 mL injection after 25 min. (i.e., a total intrathecal dose (4mL) of 12 mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ).
Study NCT06583213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional Spinal Anaesthesia.
Description: An intrathecal catheter 20 G will be then inserted 4-5 cm into the intrathecal space.This technique of SA will be performed on all patients , the needle should be inserted between L3 and L4 space or L4 and L5 space in order to avoid injury to the spinal cord. An intrathecal mixture (5mL) containing 3 mg/ml hyperbaric bupivacaine and 1 μg/ml dexmedetomidine will be prepared. Intrathecal anaesthesia will be induced by giving 2 mL (6 mg of hyperbaric bupivacaine and 2 μg of dexmedetomidine ) of the mixture, followed by a second 2 mL injection after 25 min. (i.e., a total intrathecal dose (4mL) of 12 mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ).
Study NCT06583213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Spinal Anaesthesia
Description: Intrathecal anaesthesia will be induced by giving 12.5 mg Hyperbaric bupivacaine (2.5mL) and 4 μg of dexmedetomidine (1mL) (i.e., a total intrathecal dose (3.5 mL) of 12.5mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ). (Mohamed T et al., 2017).~Sensory level will be monitored by cold spray. Haemodynamic recordings will be documented every five minutes up until 45 minutes.
Study NCT06583213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Spinal Anaesthesia
Description: Intrathecal anaesthesia will be induced by giving 12.5 mg Hyperbaric bupivacaine (2.5mL) and 4 μg of dexmedetomidine (1mL) (i.e., a total intrathecal dose (3.5 mL) of 12.5mg of hyperbaric bupivacaine and 4 μg of dexmedetomidine ). (Mohamed T et al., 2017).~Sensory level will be monitored by cold spray. Haemodynamic recordings will be documented every five minutes up until 45 minutes.
Study NCT05985330 — intervention group
Intervention type: OTHER
Intervention: Measurement of FeNO
Description: Before the first immunotherapy infusion and at the follow-up visit after the 4th course of immunotherapy
Study NCT06029452 — intervention group
Intervention type: OTHER
Intervention: Machine learning algorithm
Description: Software to calculate the predicted probability of ATTRwt-CM for these heart failure patients based on the presence and absence of certain features
Study NCT05472246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing a virtual reality headset
Description: VR group will be shown relaxing videos (nature scenes) by wearing a VR headset in addition to the routine anesthesia procedure
Study NCT05635487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811
Study NCT05635487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib
Study NCT05429528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implicit Tax
Description: This will be levied only on certain beverage categories: a 50% tax on the sales prices of carbonated drinks and sugar-sweetened beverages (SSBs) and 100% tax on the sales prices of energy drinks (milk, milk-based products, and natural fruit juice are excluded).
Study NCT05429528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explicit Tiered Tax
Description: This is an explicit tiered tax based on (underlying) Nutri-Score (NS) grades which will be levied on all food and beverages. In this arm, the investigators implement a 20% sales tax on the retail price for NS D beverages and 10% for NS D foods along with a 50% sales tax on NS E beverages and 20% on NS E foods. The NS labels will not be displayed.
Study NCT06452134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 100 MG Oral Tablet
Description: Coenzyme Q10 oral Tablet with dosage of 100mg daily given for a period of 30 days after surgery.
Study NCT06452134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Exactly same looking agent in the form of a tablet with same size and color to CoezymeQ10 with no active property given for a period of 30 days after surgery.
Study NCT05401955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: An adapted physical exercise protocol
Study NCT06147648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Sustained-release Capsules
Description: Transition from Immediate-release tacrolimus to prolonged-release tacrolimus at 3 months after liver transplantation
Study NCT05451524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insomnia prevention program
Description: Youths in the intervention group will receive 4 weekly insomnia prevention program. Each session will last for about 60-90 mins.
Study NCT06502067 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Analgesia mangement group A,B
Description: 1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .
Study NCT05451524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health education
Description: Youths in the control group will be provided with group-based general health education with same dosage (4 weeks) as intervention group.
Study NCT04048434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosorb
Description: extracorporeal cytokine adsorption
Study NCT06502067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesia mangement group A,B
Description: 1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .
Study NCT05951335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: m-Health Transition Care Program
Description: The m-Health supportive care transition program is a routine support program for caregivers of TBI patients. This program consists of education and providing face-to-face information assisted by an android-based application that can access via a smartphone, skill demonstration, assessment of the readiness of hospital discharge, as well as weekly monitoring and follow-up after the patient is discharged from the hospital. This application provides education and information on TBI caregivers regarding (a) how to treat patients with TBI at home, which includes wound care and how to provide nutrition, (b) recognize signs of infection in wounds of craniotomy, (c) recognize emergencies in cases of TBI patients at home, (d) stress management, and (e) how to arrange a schedule for the care of patients with TBI at home. This program complements routine care, which consists of education about physical health, TBI medical problems, and how to treat TBI patients at home.
Study NCT05297513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ActiveMatrix
Description: All patients will receive weight based prophylactic antibiotics i.e. Ancef, vancomycin, or clindamycin. Drains will be used in fusion cases only. Intrawound vancomycin will be used for all instrumented cases.No negative pressure devices will be used. Anatomic layers will be closed in similar, standard fashion for all cases. For those randomized to the treatment group, the ActiveMatrix product will be administered on top of the dura mater and again on the closed fascia. Those in the control group, will forgo this step.
Study NCT04678947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baxter Retching Faces (BARF) scale
Description: * Pictorial scale that was developed for use by pediatric patients in self-reported assessments of nausea severity~* A patient will respond by choosing a picture or a number on the scale that best represents how they feel. The patient may speak or simply point to their response. While the numbers 0-2-4-6-8-10 are listed alongside the pictures, patients are also allowed to choose in between or odd numbers. If a patient is unwilling to participate, the patient's parent or guardian may serve as their proxy and choose a number for them, based off of their symptoms.~* The BARF scale has 6 faces with assigned scores ranging from 0 to 10 with a score difference of 2 between each face (a higher score indicates more nausea).
Study NCT04970628 — intervention group
Intervention type: OTHER
Intervention: Medical records collection
Description: Patient's medical records before and after surgery.
Study NCT05902338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: L400 Over Ear Music Headset Glowing Cat Ear Headphones 7 branded headphones will be used for musical measurements (70-80 bpm music).
Study NCT05725551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: Before the procedure, the protruding surface of the vehicle was placed on the injection site in contact with the skin and used by holding it during injection. The level of pain and fear experienced by the child during and 5 minutes after the injection was evaluated with the Facial Expressions Pain Scale and Visual Comparison Scale, and the level of fear was evaluated with the Child Fear Scale by the child, the parent accompanying the child, and the observer.
Study NCT05725551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finger Puppet group
Description: During the interaction between the finger puppet and the child, an intramuscular injection was made. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale.
Study NCT05725551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balloon group
Description: An intramuscular injection was given when the child began to inflate the balloon. The level of pain experienced by the child during the injection and 5 minutes after the injection was evaluated by the child, the parent and the observer through the Facial Expressions Pain Scale and the Visual Comparison Scale, and the fear level by the Child Fear Scale.
Study NCT05795192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB17170
Description: Taking SB17170 orally once a day
Study NCT03772717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive vagus nerve stimulation (nVNS)
Description: The nVNS study intervention will be delivered using a handheld electrical neuromuscular stimulator device (VitalStim 400). Participants will deliver nVNS twice per day for 60 minutes each time at least 5 days per week. The two electrodes for the device will be placed on the subjects left cervical (neck) region. Parents will be trained on where to place electrodes, how to ensure that the electrodes make a good contact with the skin, and how to set the stimulation parameters. The stimulation frequency (number of pulses) and amplitude (amount of current) will be set during the initial baseline session in the clinic at a level that prevents discomfort and does not impact cardiorespiratory parameters. The stimulator will be placed in a comfortable position, such as next to the pillow. The stimulators are battery-powered and allow configuration of the stimulation parameters to the comfort of the patient.
Study NCT03772717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: Patients will be asked to continue their standard medication regimens which include in most cases will involve 3 weekly infusions of intravenous immunoglobulin (IVIG) (1 gm/kg) and rarely plasma exchange (PLEX).
Study NCT05546437 — intervention group
Intervention type: DEVICE
Intervention: Ion Endoluminal System
Description: Ion Endoluminal dye marking procedure for pulmonary nodule
Study NCT06387134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifei Xiaoji Wan
Description: The Lifei Xiaoji Wan consists of ginseng, blackhead,rhubarb, aster, forehu, and thin on.
Study NCT06387134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional treatment with Western medicine
Description: Recommended treatment protocols for patients with Stage Ia NSCLC in the Chinese Society of Oncology Branch of Lung Cancer Clinical Diagnosis and Treatment Guidelines for Lung Cancer (2021 edition) and the Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Diagnosis and Treatment Guidelines 2021.
Study NCT06381024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote patient monitoring
Description: Cureety is a digital telemonitoring platform, specifically designed to monitor signs and symptoms of disease progression and AEs in cancer patients. The digital tool is adaptable to specific treatments and disease settings. The platform collects various data including treatment delays, dose reductions, quality of life and safety data. In terms of safety, once configured for the treatment and disease setting, the patient responds to an electronic PRO (ePRO) questionnaire based on the NCI-CTCAE version (v)5.0.10 Depending on the responses, an algorithm classifies patients as either correct, compromised, state to be monitored, or critical state. Depending on the classification, patients are notified of the actions to be taken.
Study NCT04932564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide tablet
Description: Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children.~The dosing for children will be as follows:~1. \<20 kg - 100 mg x 1 day followed by 10 mg every alternate day~2. 20-40 kg - 100 mg x 2 days, followed by 10 mg daily~3. >40 kg - Usual adult dose.~This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
Study NCT06451341 — intervention group
Intervention type: BEHAVIORAL
Intervention: Acceptability of Intervention Measure (AIM)
Description: The Acceptability of Intervention Measure (AIM) questionnaire will be administered at Baseline, Month 7 and Month 15 to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The AIM will measure the extent to which participants believe CAB+RPV LA implementation is acceptable.
Study NCT06451341 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intervention Appropriateness Measure (IAM)
Description: The Intervention Appropriateness Measure (IAM) questionnaire will be administered at Baseline to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The IAM will measure the extent to which participants believe CAB+RPV LA implementation is appropriate.
Study NCT06451341 — intervention group
Intervention type: BEHAVIORAL
Intervention: Feasibility of Intervention Measure (FIM)
Description: The Feasibility of Intervention Measure (FIM) questionnaire will be administered at Baseline, Month 7 and Month 15 to patient and staff participants. This is a four-item validated measure of implementation outcomes that is often considered a leading indicator of implementation success.~The FIM will measure the extent to which participants believe CAB+RPV LA implementation is feasible.
Study NCT06451341 — intervention group
Intervention type: BEHAVIORAL
Intervention: HIV Stigma Scale Questionnaire
Description: The HIV Stigma Scale Questionnaire used in this study is a shortened version of the validated 40-item HIV stigma scale. This 12-item questionnaire measures the same four stigma subscales measured in the original version, for a streamlined approach to collecting this data on personalized stigma, disclosure concerns, concerns with public attitudes and negative self-image.~This will be administered at Baseline, Month 7 and Month 15.
Study NCT06451341 — intervention group
Intervention type: BEHAVIORAL
Intervention: HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12)
Description: The HIV Treatment Satisfaction Questionnaire was developed to evaluate treatments for HIV and patient satisfaction. The original 10 item HIVTSQ, which underwent two stages of psychometric validation, has been adapted to include questions regarding injectable treatment for HIV.~Two versions of the HIVTSQ are being used. The status version (HIVTSQs12) will assess change in treatment satisfaction over time, and the change version (HIVTSQc12) will assess the change in treatment satisfaction between a patient participant's previous and current treatment.~The status version will be administered at Baseline, Month 7 and Month 15.
Study NCT06451341 — intervention group
Intervention type: BEHAVIORAL
Intervention: HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12)
Description: The HIV Treatment Satisfaction Questionnaire was developed to evaluate treatments for HIV and patient satisfaction. The original 10 item HIVTSQ, which underwent two stages of psychometric validation, has been adapted to include questions regarding injectable treatment for HIV.~Two versions of the HIVTSQ are being used. The status version (HIVTSQs12) will assess change in treatment satisfaction over time, and the change version (HIVTSQc12) will assess the change in treatment satisfaction between a patient participant's previous and current treatment.~The change version will be administered at Month 15.